Emcure Pharmaceuticals Limited has submitted its quarterly confirmation certificate under SEBI regulations to the stock exchanges, demonstrating compliance with depositories and participants regulations for the quarter ended March 31, 2026.

Regulatory Filing Details

The pharmaceutical company filed the confirmation certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 on April 07, 2026. The certificate was submitted to both the National Stock Exchange of India Limited and BSE Limited as part of the company's regulatory compliance requirements.

Registrar Confirmation

MUFG Intime India Private Limited, formerly known as Link Intime India Private Limited, serves as the company's Registrar and Share Transfer Agent (RTA). The registrar provided the confirmation certificate dated April 06, 2026, certifying compliance with dematerialisation procedures during the quarter.

The registrar confirmed that securities received from depository participants for dematerialisation during the quarter ended March 31, 2026 were properly processed. All securities comprised in the certificates have been listed on the stock exchanges where the company's earlier issued securities are listed.

Compliance Procedures

The certificate confirms that security certificates received for dematerialisation were properly handled according to regulatory requirements. Key compliance aspects include:

• Securities received from depository participants were confirmed or rejected to depositories within prescribed timelines
• Security certificates received were mutilated and cancelled after due verification by depository participants
• Names of depositories were substituted in the register of members as registered owners
• All procedures followed prescribed regulatory timelines

Company Information

The filing was signed by Amruta Yangalwar, Company Secretary and Compliance Officer, who holds ICSI Membership No: A25687. The company maintains its registered office at Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune.

Emcure Pharmaceuticals has announced a significant price reduction for its weight management drug Poviztra® (semaglutide injection) across India, effective April 3, 2026. The pharmaceutical company has reduced the starting dose price by 55% to ₹3,999 per month, marking a substantial step toward improving patient access to essential obesity treatment.

Major Price Reduction Initiative

The company has implemented comprehensive pricing restructure for Poviztra® across all dosage strengths. As the first Indian company to exclusively distribute and commercialize Poviztra®, a second brand of Novo Nordisk's semaglutide injection for obesity, Emcure aims to expand access and enable more patients to benefit from this proven therapy.

Addressing India's Obesity Challenge

The price revision comes at a critical time when obesity and weight-related health conditions are emerging as one of India's most pressing public health challenges. According to recent data, nearly 254 million people are living with generalized obesity and 351 million with abdominal obesity in India.

Satish Mehta, Chief Executive Officer and Managing Director, Emcure Pharma, stated: "The revised pricing of Poviztra® is a step towards making scientifically validated weight-management therapies more accessible and affordable to a wider patient base. Improving access to a globally established molecule like semaglutide is crucial to addressing this public health challenge at scale."

Product Features and Clinical Evidence

Poviztra® is available in a once-weekly pen device in five strengths: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg and a maintenance dose of 2.4 mg. The state-of-the-art pen device provides convenience of simple administration and precise dosing. The innovator biologic rDNA semaglutide molecule has been on the market for close to a decade and is backed by nearly 50 clinical trials in diverse clinical settings, with an equivalent of 49+ million patient years of exposure.

Obesity is linked to over 230 health complications including cardiovascular disease, type 2 diabetes, hypertension, fatty liver, knee osteoarthritis, polycystic ovary syndrome, kidney disease and Alzheimer's disease. With this price reduction, Emcure Pharma reinforces its commitment to advancing patient access, improving health outcomes, and supporting innovative treatments that address the growing burden of obesity in India.

Source: None/Company/INE168P01015/8f5492a5-8612-4da0-aa85-2d0e0e672304.pdf